|
Malignant neoplasm of stomach
|
0.010 |
Biomarker
|
disease |
BEFREE |
We show that wild-type <i>IDH1</i> is essential for GC cell survival, and that certain GC cells can be targeted by IDH1 inhibitors.
|
31068366 |
2020 |
|
Stomach Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
We show that wild-type <i>IDH1</i> is essential for GC cell survival, and that certain GC cells can be targeted by IDH1 inhibitors.
|
31068366 |
2020 |
|
Grade III Chondrosarcoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Genomic Profiling Identifies Association of <i>IDH1/IDH2</i> Mutation with Longer Relapse-Free and Metastasis-Free Survival in High-Grade Chondrosarcoma.
|
31615936 |
2020 |
|
Diffuse Astrocytoma, IDH-Wildtype
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Anaplastic astrocytoma, IDH-wildtype (AA-IDHwt) was the common molecular subgroup (52.8%), followed by diffuse astrocytoma, IDH-wildtype (DA-IDHwt) and AA, IDH-mutant (AA-IDHmt) (each 16.9%), DA-IDHmt (7.9%), glioblastoma (GBM)-IDHwt (3.3%) and GBM-IDHmt (2.2%).
|
31435963 |
2020 |
|
Anaplastic Astrocytoma, IDH-Wildtype
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Anaplastic astrocytoma, IDH-wildtype (AA-IDHwt) was the common molecular subgroup (52.8%), followed by diffuse astrocytoma, IDH-wildtype (DA-IDHwt) and AA, IDH-mutant (AA-IDHmt) (each 16.9%), DA-IDHmt (7.9%), glioblastoma (GBM)-IDHwt (3.3%) and GBM-IDHmt (2.2%).
|
31435963 |
2020 |
|
Alzheimer's Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
The IDP amyloid β-protein (Aβ) has been both the prime causative suspect and drug development target in the fight against Alzheimer's disease (AD).
|
31521233 |
2019 |
|
Aortic Valve Insufficiency
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Chromatin immunoprecipitation experiments confirmed the recruitment of AR at several regulatory regions of <i>IDH1</i> and enzymatic assays demonstrated that AR significantly induces IDH activity.
|
31068457 |
2019 |
|
Heartburn
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
An imaging biomarker combining tumor acidity and hypoxia (MTRasymxR2') can differentiate IDH1 mutation status and is correlated with tumor acidity and hypoxia.
|
31066901 |
2019 |
|
Respiratory Tract Infections
|
0.010 |
Biomarker
|
group |
BEFREE |
IDP-73152 mesylate is a peptide deformylase inhibitor under investigation for the treatment of complicated skin and respiratory tract infections.
|
31440032 |
2019 |
|
Acute myeloid leukemia in remission
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Monitoring for persistent <i>IDH1/2</i> mutations in patients with acute myeloid leukemia in remission can provide information that could be used to justify early interventions, with the hope of facilitating longer remissions and better outcomes in these patients.
|
30171025 |
2019 |
|
Metastatic melanoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Oxalomalate suppresses metastatic melanoma through IDH-targeted stress response to ROS.
|
31020875 |
2019 |
|
Parathyroid Gland Adenocarcinoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Nine PC samples (47%) harbored at least one potentially actionable genomic alteration including in the after genes: ROS1 (5/19; 26%), PTEN (3/19; 16%), TSC1 (2/19; 11%), PIK3CA (1/19; 5%), AKT1 (1/19; 5%), MTOR (1/19; 5%), ERBB2 (1/19; 5%), NTRK1 (1/19; 5%), IDH1 (1/19; 5%) and FGFR3 (1/19; 5%).
|
30362515 |
2019 |
|
Malignant neoplasm of ovary
|
0.010 |
Biomarker
|
disease |
BEFREE |
Targeting IDH1 as a Prosenescent Therapy in High-grade Serous Ovarian Cancer.
|
31110157 |
2019 |
|
Sinonasal undifferentiated carcinoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Literature search revealed a virtual absence of IDH2 R172 and IDH1 R132S mutations in >1000 cases of 8 different malignancies included in the differential diagnosis of sinonasal undifferentiated carcinoma.
|
30206411 |
2019 |
|
Acute Myeloid Leukemia with Myelodysplasia-Related Changes
|
0.010 |
Biomarker
|
disease |
BEFREE |
The therapeutic landscape is rapidly changing, with eight new drugs approved by the Food and Drug Administration within the last 2 years, including midostaurin and gilteritinib for FLT3 mutant newly diagnosed and relapsed/refractory (R/R) acute myeloid leukemia (AML), respectively; CPX-351 (liposomal cytarabine and daunorubicin) for therapy-related AML and AML with myelodysplasia-related changes; gemtuzumab ozogamicin (anti-CD33 monoclonal antibody conjugated with calicheamicin) for newly diagnosed and R/R CD33-positive AML; enasidenib and ivosidenib for IDH2 and IDH1 mutant R/R AML, respectively.
|
30861214 |
2019 |
|
Acute myeloid leukemia with mutated NPM1
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
TET2 and IDH1/2 mutations were significantly more common in DN AML-NPM1 (96% of cases) than in myeloid (39%) or monocytic AML-NPM1 (48%; P < .0001).
|
31698462 |
2019 |
|
Triple Negative Breast Neoplasms
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Using targeted sequencing, we detected somatic mutation-related discordant breast cancer including the VHL gene in the HR+/HER2- group (31% in concordant group, 0% in discordant group, p=0.03) and the IDH and RET genes (7% vs. 12%, p=0.02 and 0% vs. 25%, p=0.02, respectively) in the TNBC group.
|
30189722 |
2019 |
|
High grade serous carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
IMPLICATIONS: Inhibition of IDH1 may act as a novel therapeutic approach to alter both the metabolism and epigenetics of HGSC as a prosenescent therapy.
|
31110157 |
2019 |
|
Diffuse leptomeningeal glioneuronal neoplasm
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
This tumor showed genotypes frequently found in DLGNT such as 1p/19q codeletion without IDH mutation and, however, did not have the typical DLGNT clinical and histological features.
|
31011918 |
2019 |
|
Carcinoma, Ovarian Epithelial
|
0.010 |
Biomarker
|
disease |
BEFREE |
Targeting IDH1 as a Prosenescent Therapy in High-grade Serous Ovarian Cancer.
|
31110157 |
2019 |
|
Triple-Negative Breast Carcinoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Using targeted sequencing, we detected somatic mutation-related discordant breast cancer including the VHL gene in the HR+/HER2- group (31% in concordant group, 0% in discordant group, p=0.03) and the IDH and RET genes (7% vs. 12%, p=0.02 and 0% vs. 25%, p=0.02, respectively) in the TNBC group.
|
30189722 |
2019 |
|
Malignant neoplasm of breast
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In this study, the clinical impact of IDH1 expression on the progression and prognosis of breast cancer was evaluated using immunohistochemistry assay (IHC) of the corresponding tumor-adjacent normal, ductal carcinoma in situ (DCIS), and invasive ductal carcinoma (IDC) tissues from 309 patients with breast ductal carcinoma.
|
29661250 |
2018 |
|
Malignant neoplasm of endometrium
|
0.010 |
Biomarker
|
disease |
BEFREE |
However, whether IDH1 play a role in metformin-induced endometrial cancer chemosensitivity through epigenetic modification is incompletely understood.
|
29921847 |
2018 |
|
Noninfiltrating Intraductal Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In this study, the clinical impact of IDH1 expression on the progression and prognosis of breast cancer was evaluated using immunohistochemistry assay (IHC) of the corresponding tumor-adjacent normal, ductal carcinoma in situ (DCIS), and invasive ductal carcinoma (IDC) tissues from 309 patients with breast ductal carcinoma.
|
29661250 |
2018 |
|
Chediak-Higashi Syndrome
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
In CHS, IDH1/2-mutation status and the histological aggressiveness of the CHS are important predictors for OS.
|
29581779 |
2018 |